Loading…
Loading…
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $49.39, marking a -1.2% move from the previous day.
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
ZUG, Switzerland and BOSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that its Chief Financial Officer, Raju Prasad, Ph.D., will be stepping down from the Company to pursue external opportunities, and A.J.
CRISPR Therapeutics has an approved product on the market that could gain significant commercial traction over the medium term. The company could also make substantial pipeline and regulatory progress.
CRISPR Therapeutics' shares have declined more than 25% over the past year. The gene-editing biotech has one approved therapy, Casgevy.
CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $49.21, signifying a -4.48% move from its prior day's close.
CRISPR Therapeutics AG (CRSP) closed at $51.55 in the latest trading session, marking a -3.45% move from the prior day.